Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Operating Leases: 2023-2025

Historic Operating Leases for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $4.0 million.

  • Contineum Therapeutics' Operating Leases was N/A to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 4350.93% up from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Operating Leases is $4.0 million, which was down 6.26% from $4.3 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Operating Leases high stood at $4.8 million for Q4 2024, and its period low was $108,000 during Q4 2023.
  • Moreover, its 3-year median value for Operating Leases was $4.0 million (2025), whereas its average is $2.6 million.
  • Data for Contineum Therapeutics' Operating Leases shows a peak YoY surged of 4,350.93% (in 2024) over the last 5 years.
  • Over the past 3 years, Contineum Therapeutics' Operating Leases (Quarterly) stood at $108,000 in 2023, then skyrocketed by 4,350.93% to $4.8 million in 2024, then surged by 3,691.15% to $4.0 million in 2025.
  • Its Operating Leases was $4.0 million in Q3 2025, compared to $4.3 million in Q2 2025 and $4.5 million in Q1 2025.